The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- MHLW Grants Orphan Status to Cx601, Takeda’s 1st Cell Therapy
March 15, 2019
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- HSC Committee Continues to Discuss Reorganizing Core Clinical Research Hospitals
March 15, 2019
- Xofluza-Resistant Viruses Detected in Xofluza-Naïve Patients: NIID
March 15, 2019
- MHLW’s Panel Compiles Interim Paper for Promotion of Clinical Research, Trials
March 14, 2019
- Dismissal Order Provision Erased from PMD Law Amendment Bill
March 14, 2019
- MHLW Calls for Cooperation in Genomic Research on Drug-Induced Muscle Disorders
March 14, 2019
- MHLW to Promote Master Protocol Trials to Boost Efficiency in New Drug Development
March 14, 2019
- MHLW Likely to Tweak PMD Law Amendment Bill as Lawmaker Frowns on Order to Change Pharmaceutical Affairs Officer
March 13, 2019
- MHLW Panel Approves Shift from “Relative Contraindications” to “Contraindications” for 5 Drugs/Drug Groups
March 13, 2019
- Detailing Guidelines Casting Clouds over Drug Maker-Sponsored Press Seminars?
March 12, 2019
- Japan Issues 1st Guidance on Cancer Immunotherapy Development
March 11, 2019
- Govt to Ponder Appropriate Ways to Offer Off-Label Info to Patients
March 11, 2019
- LDP Wraps Up Review on Bill to Amend PMD Law; Cabinet OK Eyed in Mid-March
March 8, 2019
- LDP Panels Approve Proposal to Promote Regulatory Harmonization, Improve Access in Asia
March 8, 2019
- Chuikyo Approves Discussion Timeline for FY2020 Reimbursement Reform; Drug Pricing Debates Expected from June
March 7, 2019
- MHLW Grants Orphan Status to Adcetris, Evocalcet and More
March 6, 2019
- PMDA Sacks Employee for Doing Side Business with Companies with COI
March 5, 2019
- Xofluza Ordered to Add Hemorrhage Risk to Its Label
March 4, 2019
- Tagrisso Label Notes Previous Opdivo Use as Risk Factor for ILD
March 1, 2019
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…